Abstract
Summary
Asia-Pacific genetic testing market is expected to reach USD 15,964,607.02 thousand by 2031 from USD 4,482,551.35 thousand in 2023 with growing at a CAGR of 17.5% during the forecast period of 2024 to 2031.
Market Segmentation
Asia-Pacific Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), By Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031
Overview of Global Genetic Testing Market Dynamics
Driver
• Growing prevalence of genetic disorders
Restrain
• High cost of genetic testing
Opportunity
• Strategic initiatives by the key market player
Market Players
Some of the key market players for Asia-Pacific genetic testing market are:
• Thermo Fisher Scientific Inc.
• Invitae Corporation
• Bio-Rad Laboratories, Inc.
• PerkinElmer Inc.
• Illumina, Inc.
• QIAGEN
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics
• Myriad Genetics, Inc.
• Abbott
• Eurofins Scientific
• Sorenson Genomics
• BIO-HELIX
• Biocartis
• Cepheid (A subsidiary of Danaher)
• PacBio
• ELITechGroup
• Genes2Me
• Eugene Labs
• Otogenetics
• Mapmygenome
• MedGenome
• BioReference
• Natera, Inc.
Table of Contents
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW OF THE ASIA PACIFIC GENETIC TESTING MARKET 67
1.4 LIMITATIONS 69
1.5 MARKETS COVERED 69
2 MARKET SEGMENTATION 72
2.1 MARKETS COVERED 72
2.2 GEOGRAPHICAL SCOPE 73
2.3 YEARS CONSIDERED FOR THE STUDY 74
2.4 CURRENCY AND PRICING 74
2.5 DBMR TRIPOD DATA VALIDATION MODEL 75
2.6 TYPE LIFELINE CURVE 79
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.8 DBMR MARKET POSITION GRID 81
2.9 MARKET APPLICATION COVERAGE GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 87
4.1 PESTAL ANALYSIS 90
4.2 PORTERS 5 FORCES 91
4.3 EPIDEMIOLOGY 92
5 ASIA PACIFIC GENETIC TESTING MARKET: REGULATIONS 93
6 MARKET OVERVIEW 95
6.1 DRIVERS 97
6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 97
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 97
6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 98
6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 98
6.2 RESTRAINTS 99
6.2.1 HIGH COST OF GENETIC TESTING 99
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 100
6.3 OPPORTUNITIES 100
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 100
6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 101
6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 101
6.4 CHALLENGES 102
6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 102
6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 103
7 ASIA PACIFIC GENETIC TESTING MARKET, BY TYPE 104
7.1 OVERVIEW 105
7.2 DIAGNOSTIC TESTING 109
7.3 PRENATAL TESTING 109
7.3.1 NON-INVASIVE SCREENING 110
- 7.3.1.1 WHOLE GENOME SEQUENCING 111
- 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 111
- 7.3.1.3 OTHERS 111
7.3.2 BY CONDITION 112
- 7.3.2.1 TRISOMY 21 112
- 7.3.2.2 KLINEFELTER SYNDROME 112
- 7.3.2.3 JACOBS SYNDROME 112
- 7.3.2.4 CYSTIC FIBROSIS 112
- 7.3.2.5 TURNER SYNDROME 113
- 7.3.2.6 TRISOMY 18 113
- 7.3.2.7 HEMOPHILIA 113
- 7.3.2.8 TRISOMY 13 113
- 7.3.2.9 MICRODELETION SYNDROME 113
- 7.3.2.10 FETAL GENDER 113
- 7.3.2.11 OTHERS 113
7.3.3 BY SCREENING TYPE 114
- 7.3.3.1 CARRIER SEQUENCING 114
- 7.3.3.2 SEQUENTIAL SEQUENCING 114
7.3.4 MATERNAL SERUM QUAD SCREENING 114
7.4 NEW-BORN SCREENING 115
7.4.1 SICKLE CELL DISEASE 115
7.4.2 CONGENITAL HYPOTHYROIDISM 116
7.4.3 PHENYLKETONURINA (PKU) 116
7.4.4 GALACTOSEMIA 116
7.4.5 MAPLE SYRUP URINE DISEASE 116
7.4.6 OTHERS 116
7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 116
7.6 CARRIER TESTING 117
7.6.1 MOLECULAR SCREENING TEST 117
7.6.2 BIOCHEMICAL SCREENING TEST 118
- 7.6.2.1 EXPANDED CARRIER SCREENING 118
- 7.6.2.2 PREDESIGNED PANEL TESTING 119
- 7.6.2.3 CUSTOM-MADE PANEL TESTING 119
- 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 119
- 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 119
- 7.6.2.4.2 PULMONARY CONDITIONS 120
- 7.6.2.4.3 NEUROLOGICAL CONDITIONS 120
- 7.6.2.4.4 OTHER CONDITIONS 120
7.7 OTHER TYPES 120
8 ASIA PACIFIC GENETIC TESTING MARKET, BY TECHNOLOGY 121
8.1 OVERVIEW 122
8.2 POLYMERASE CHAIN REACTION 125
8.2.1 REAL-TIME PCR (QPCR) 126
8.2.2 DIGITAL PCR (DPCR) 126
8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 126
8.2.4 HOT-START PCR 126
8.2.5 MULTIPLEX PCR 126
8.2.6 OTHER PCR 126
8.3 DNA SEQUENCING (NGS-BASED TESTING) 127
8.3.1 NEXT GENERATION SEQUENCING (NGS) 127
8.3.2 SANGER SEQUENCING (SINGLE GENE) 127
8.3.3 OTHER 128
8.4 WHOLE GENOME SEQUENCING 128
8.5 MICROARRAYS 128
8.5.1 DNA MICROARRAYS 129
8.5.2 PROTEIN MICROARRAYS 129
8.5.3 OTHER MICROARRAYS 129
8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 129
8.7 OTHERS 130
9 ASIA PACIFIC GENETIC TESTING MARKET, BY DISEASES 131
9.1 OVERVIEW 132
9.2 CANCER 135
9.2.1 BREAST 136
9.2.2 COLON 136
9.2.3 LUNG 136
9.2.4 PROSTATE 136
9.2.5 OTHERS 136
9.3 SICKLE CELL ANEMIA 137
9.4 THALASSEMIA 137
9.5 RARE GENETIC DISORDER 138
9.5.1 TRISOMY 21 138
9.5.2 MONOSOMY X 138
9.5.3 TRISOMY 13 139
9.5.4 MICRODELETION SYNDROME 139
9.5.5 TRISOMY 18 139
9.5.6 OTHERS 139
9.6 FRAGILE X SYNDROME 139
9.7 DUCHENNE MUSCULAR DYSTROPHY 140
9.8 HUNTINGTON'S DISEASE 140
9.9 CYSTIC FIBROSIS 141
9.10 OTHERS 141
10 ASIA PACIFIC GENETIC TESTING MARKET, BY END USER 142
10.1 OVERVIEW 143
10.2 HOSPITALS 146
10.3 CLINICS 147
10.4 DIAGNOSTIC CENTERS 147
10.5 PRIVATE CLINICS 148
10.6 LABORATORY SERVICE PROVIDERS 148
10.7 PRIVATE LABORATORIES 149
11 ASIA PACIFIC GENETIC TESTING MARKET, BY REGION 150
11.1 ASIA-PACIFIC 152
11.1.1 CHINA 161
11.1.2 JAPAN 172
11.1.3 INDIA 183
11.1.4 SOUTH KOREA 194
11.1.5 AUSTRALIA 205
11.1.6 SINAGPORE 216
11.1.7 THAILAND 227
11.1.8 INDONESIA 238
11.1.9 PHILIPPINES 249
11.1.10 MALAYSIA 260
11.1.11 VIETNAM 271
11.1.12 REST OF ASIA-PACIFIC 282
12 ASIA PACIFIC GENETIC TESTING MARKET, COMPANY LANDSCAPE 283
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 283
13 SWOT ANALYSIS 284
14 COMPANY PROFILES 285
14.1 ILLUMINA, INC 285
14.1.1 COMPANY SNAPSHOT 285
14.1.2 REVENUE ANALYSIS 285
14.1.3 COMPANY SHARE ANALYSIS 286
14.1.4 PRODUCT PORTFOLIO 286
14.1.5 RECENT DEVELOPMENT 287
14.2 CEPHEID 288
14.2.1 COMPANY SNAPSHOT 288
14.2.2 REVENUE ANALYSIS 288
14.2.3 COMPANY SHARE ANALYSIS 289
14.2.4 PRODUCT PORTFOLIO 289
14.2.5 RECENT DEVELOPMENT 289
14.3 FULGENT GENETICS 290
14.3.1 COMPANY SNAPSHOT 290
14.3.2 REVENUE ANALYSIS 290
14.3.3 COMPANY SHARE ANALYSIS 291
14.3.4 PRODUCT PORTFOLIO 291
14.3.5 RECENT DEVELOPMENT 292
14.4 PERKINELMER INC 293
14.4.1 COMPANY SNAPSHOT 293
14.4.2 REVENUE ANALYSIS 293
14.4.3 COMPANY SHARE ANALYSIS 294
14.4.4 PRODUCT PORTFOLIO 294
14.4.5 RECENT DEVELOPMENT 294
14.5 THERMO FISHER SCIENTIFIC INC 295
14.5.1 COMPANY SNAPSHOT 295
14.5.2 REVENUE ANALYSIS 295
14.5.3 COMPANY SHARE ANALYSIS 296
14.5.4 PRODUCT PORTFOLIO 296
14.5.5 RECENT DEVELOPMENT 297
- 14.5.5.1 COLLABORATION 297
14.6 BIOREFERENCE 298
14.6.1 COMPANY SNAPSHOT 298
14.6.2 REVENUE ANALYSIS 298
14.6.3 PRODUCT PORTFOLIO 299
14.6.4 RECENT DEVELOPMENT 299
14.7 ELITECHGROUP 300
14.7.1 COMPANY SNAPSHOT 300
14.7.2 PRODUCT PORTFOLIO 300
14.7.3 RECENT DEVELOPMENTS 301
14.8 EUROFINS SCIENTIFIC 302
14.8.1 COMPANY SNAPSHOT 302
14.8.2 REVENUE ANALYSIS 302
14.8.3 PRODUCT PORTFOLIO 303
14.8.4 RECENT DEVELOPMENT 303
14.9 INVITAE CORPORATION 304
14.9.1 COMPANY SNAPSHOT 304
14.9.2 REVENUE ANALYSIS 304
14.9.3 PRODUCT PORTFOLIO 305
14.9.4 RECENT DEVELOPMENTS 305
14.10 MYRIAD GENETICS 306
14.10.1 COMPANY SNAPSHOT 306
14.10.2 REVENUE ANALYSIS 306
14.10.3 PRODUCT PORTFOLIO 307
14.10.4 RECENT DEVELOPMENT 307
14.11 ABBOTT 308
14.11.1 COMPANY SNAPSHOT 308
14.11.2 REVENUE ANALYSIS 308
14.11.3 PRODUCT PORTFOLIO 309
14.11.4 RECENT DEVELOPMENT 309
14.12 BIOCARTIS 310
14.12.1 COMPANY SNAPSHOT 310
14.12.2 REVENUE ANALYSIS 310
14.12.3 PRODUCT PORTFOLIO 311
14.12.4 RECENT DEVELOPMENTS 311
- 14.12.4.1 PARTNERSHIP 311
14.13 BIO-HELIX 312
14.13.1 COMPANY SNAPSHOT 312
14.13.2 PRODUCT PORTFOLIO 312
14.13.3 RECENT DEVELOPMENT 312
14.14 BIO-RAD LABORATORIES, INC 313
14.14.1 COMPANY SNAPSHOT 313
14.14.2 REVENUE ANALYSIS 313
14.14.3 PRODUCT PORTFOLIO 314
14.14.4 RECENT DEVELOPMENTS 314
14.15 EUGENE LABS 315
14.15.1 COMPANY SNAPSHOT 315
14.15.2 PRODUCT PORTFOLIO 315
14.15.3 RECENT DEVELOPMENT 315
14.16 F. HOFFMANN-LA ROCHE LTD 316
14.16.1 COMPANY SNAPSHOT 316
14.16.2 REVENUE ANALYSIS (PARENT COMPANY) 316
14.16.3 PRODUCT PORTFOLIO 317
14.16.4 RECENT DEVELOPMENT 317
14.17 GENES2ME 318
14.17.1 COMPANY SNAPSHOT 318
14.17.2 PRODUCT PORTFOLIO 318
14.17.3 RECENT DEVELOPMENT 318
14.18 MAPMYGENOME 319
14.18.1 COMPANY SNAPSHOT 319
14.18.2 PRODUCT PORTFOLIO 319
14.18.3 RECENT DEVELOPMENT 320
14.19 MEDGENOME 321
14.19.1 COMPANY SNAPSHOT 321
14.19.2 PRODUCT PORTFOLIO 321
14.19.3 RECENT DEVELOPMENT 322
14.20 NATERA, INC 323
14.20.1 COMPANY SNAPSHOT 323
14.20.2 REVENUE ANALYSIS 323
14.20.3 PRODUCT PORTFOLIO 324
14.20.4 RECENT DEVELOPMENT 325
14.21 OTOGENETICS 326
14.21.1 COMPANY SNAPSHOT 326
14.21.2 PRODUCT PORTFOLIO 327
14.21.3 RECENT DEVELOPMENT 327
14.22 PACBIO 328
14.22.1 COMPANY SNAPSHOT 328
14.22.2 REVENUE ANALYSIS 328
14.22.3 PRODUCT PORTFOLIO 329
14.22.4 RECENT DEVELOPMENT 329
14.23 QIAGEN 330
14.23.1 COMPANY SNAPSHOT 330
14.23.2 REVENUE ANALYSIS 330
14.23.3 PRODUCT PORTFOLIO 331
14.23.4 RECENT DEVELOPMENT 331
14.24 SORENSON GENOMICS 332
14.24.1 COMPANY SNAPSHOT 332
14.24.2 PRODUCT PORTFOLIO 332
14.24.3 RECENT DEVELOPMENT 332
15 QUESTIONNAIRE 333
16 RELATED REPORTS 336